Evonik rejects BASF's €10.3 billion takeover bid, sources say

Common ground

• All participants agree the deal is likely to happen within 18 months at a higher price, around €11.5-12 billion.
• There is broad agreement that the RAG Foundation, holding 44% of Evonik, is the key decision-maker and will sell if the price is right.
• Everyone acknowledges that the European Commission has approved every major chemical merger with minor remedies since 2015, which is seen as a pattern of weak oversight.
• All sides agree that the Global South—farmers, manufacturers, and workers in developing countries—has no voice in this deal and will be affected by supply chain consolidation.
• There is consensus that BASF's rejection of the €10.3 billion offer is a negotiating tactic, not a principled stand for independence.

Points of contention

• Neutral Agent argues the deal is purely about price and corporate strategy, while Western Agent insists it reflects a democratic deficit and political failure in European industrial policy.
• Regional Agent claims the deal is a double standard where Western consolidation is praised but Global South protectionism is punished, but Neutral Agent and Eastern Agent reject this as a false equivalence with IMF-mandated privatizations.
• Eastern Agent says BASF is defensively consolidating because China has already won the greenfield investment race, but Neutral Agent counters that BASF's €10 billion Zhanjiang investment proves they are hedging, not retreating.
• Western Agent argues the merger will accelerate job losses, while Neutral Agent says scale efficiencies could preserve some roles and cites DowDuPont as a counterexample.
• Regional Agent and Eastern Agent emphasize the deal deepens Global South dependency, but Neutral Agent argues specialty chemical markets have multiple suppliers and scale reduces costs.

Blind spots

• No one has quantified the operational cost of the 6-9 month regulatory review period, during which both companies cannot integrate or cut costs.
• The potential for the RAG Foundation to accept BASF shares instead of cash, making them a major BASF shareholder, has been mentioned but not fully explored as a game-changing structure.
• The silence from Beijing and how China's state-backed chemical expansion will respond to this consolidation has been noted but not analyzed in depth.
• The specific impact on pharmaceutical intermediates and animal feed supply chains in developing countries has been raised but lacks concrete data or historical precedent.
• The role of worker representation and public debate in the merger process has been highlighted by Western Agent but not addressed by other participants.

WorldAttention’s read

This debate reveals that the BASF-Evonik story is less about a failed deal and more about a price negotiation disguised as strategic drama. All sides agree the merger will likely happen within 18 months at a higher price, with the RAG Foundation as the key player. The core disagreement is whether this is a rational corporate move or a symptom of deeper problems: a democratic deficit in European industrial policy, double standards between Western consolidation and Global South protectionism, and the end of Western dominance in chemicals as China rises. The blind spots are significant—no one has fully explored the financing structure, the regulatory timeline costs, or the concrete impact on developing countries. Ultimately, the deal is a test case for whether Europe can compete through innovation or will rely on consolidation, and the Global South remains a silent bystander in a conversation that will reshape the supply chains they depend on.